Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 3, pp 316–318 | Cite as

Unusual drug reaction between valproate sodium and meropenem

  • Hyonok YoonEmail author
  • Diana H. Kim
Case Report

Abstract

Case We describe here a rare case in which valproic acid (VPA) levels were affected by ertapenem but not by meropenem even though ertapenem and meropenem are in the same carbapenem class. A 68-year-old Filipino male treated with valproate for epilepsy and ertapenem for an infectious disease had decreased VPA levels during the first day of ertapenem therapy. His VPA level increased soon after terminating ertapenem therapy. Two types of carbapenems had different drug reactions with concomitant use of VPA in this patient. Conclusions Closer monitoring of VPA concentrations are necessitated using carbapenems for treating infection in patients being administered VPA. Another option is the use of anti-epileptic drugs other than VPA if concomitant use with a carbapenem is warranted.

Keywords

Drug interaction Epilepsy Ertapenem Meropenem Valproic acid 

Notes

Acknowledgments

None.

Funding

None.

Conflicts of interest

None to declare.

References

  1. 1.
    Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol. 1999;58(1):31–59.PubMedCrossRefGoogle Scholar
  2. 2.
    Rimmer EM, Richens A. An update on sodium valproate. Pharmacotherapy. 1985;5(3):171–84.PubMedGoogle Scholar
  3. 3.
    Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev. 2007;39(4):647–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Torii M, Takiguchi Y, Saito F, Izumi M, Yokota M. Inhibition by carbapenem antibiotic imipenem of intestinal absorption of valproic acid in rats. J Pharm Pharmacol. 2001;53(6):823–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Omoda K, Murakami T, Yumoto R, Nagai J, Maeda Y, Kiribayashi Y, et al. Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human. J Pharm Sci. 2005;94(8):1685–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Yokogawa K, Iwashita S, Kubota A, Sasaki Y, Ishizaki J, Kawahara M, et al. Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. Pharm Res. 2001;18(9):1320–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Nakamura Y, Nakahira K, Mizutani T. Decreased valproate level caused by VPA-glucuronidase inhibition by carbapenem antibiotics. Drug Metab Lett. 2008;2(4):280–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Fernandez Garcia MI, de la Puebla Fernandez, Gimenez RA, Garcia Olid B, Torres Degayon V. Meropenem decreases valproate plasmatic concentrations. Med Clin (Barc). 2011;137(1):43–4.CrossRefGoogle Scholar
  9. 9.
    Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol. 2004;31(3):232–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of Clinical Pharmacy, College of PharmacyChonnam National UniversityGwangjuRepublic of Korea
  2. 2.Department of Pharmacotherapeutics, College of Pharmacy, Research Institute of Pharmaceutical SciencesGyeongsang National UniversityJinju, GyeongnamRepublic of Korea
  3. 3.Department of Biology, College of Arts and SciencesUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations